Antithrombotic Effects of FK419, a Novel Nonpeptide Platelet GPIIb/IIIa Antagonist, in a Guinea Pig Photochemically Induced Middle Cerebral Artery Thrombosis Model: Comparison with Ozagrel and Argatroban

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 3, 2004, Pages 1094-1101

  Moriguchi, Akira ^a   Aoki, Toshiaki ^a   Mihara, Kayoko ^a   Tojo, Nobuteru ^a   Matsuoka, Nobuya ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETYLAMINO 3 [[1 [3 (PIPERIDIN 4 YL)PROPIONYL]PIPERIDIN 3 YLCARBONYL]AMINO]PROPIONIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; FIBRINOGEN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FK 419; OZAGREL; THROMBIN INHIBITOR; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; GUINEA PIG; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PATHOGENESIS; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; TREATMENT OUTCOME; VASCULAR PATENCY;

ANIMALS; ANTITHROMBINS; BLOOD COAGULATION; BLOOD PLATELETS; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; GUINEA PIGS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; METHACRYLATES; PIPECOLIC ACIDS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; REPERFUSION INJURY; THROMBOXANE B2;

EID: 1342302105     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.058073     Document Type: Article

References (41)

1. IIbβ3 inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia. Stroke 31:1402-1410.
2. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106. Erratum in Br Med J (1994) 308:1540.
3. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 308:81-106. Erratum in Br Med J (1994) 308:1540.
4. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis R, and Bartkowski H (1986) Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 17:472-476.
5. Bednar MM and Gross CE (1999) Aspirin reduces experimental cerebral blood flow in vivo. Neurol Res 21:488-490.
6. CAST (Chinese Acute Stroke Trial) Collaborative Group (1997) CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 349:1641-1649.
7. Chen ZM, Sandercock P, Pan HC, Counsell C, Collins R, Liu LS, Xie JX, Warlow C, and Peto R (2000) Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 31:1240-1249.
8. Choudhri TF, Hoh BL, Zerwes HG, Prestigiacomo CJ, Kim SC, Connolly ES Jr, Kottirsch G, and Pinsky DJ (1998) Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GPIIb/IIIa receptor-mediated platelet aggregation. J Clin Investig 102:1301-1310.
9. Collar BS, Anderson K, and Weisman HF (1995) New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemostasis 74:302-308.
10. Collen D and Lijnen HR (1991) Thrombolytic therapy. Ann NY Acad Sci 614:259-269.
11. Cook NS, Kottirsch G, and Zerwes H-G (1994) Platelet glycoprotein IIb/IIIa antagonists. Drugs Future 19:135-159.
12. Domanovits H, Nikfardjam M, Janata K, Hornykewycz S, Maurer G, Laggner AN, and Huber K (1998) Restoration of coronary blood flow by single bolus injection of the GPIIb/IIIa receptor antagonist c7E3 Fab in a patient with acute myocardial infarction of recent onset. Clin Cardiol 21:525-528.
13. Figols J, Cervós-Navarro J, Sampaolo S, and Ferszt R (1987) Microthrombi in the development of ischemic irreversible brain infarct, in Stroke and Microcirculation (Cervós-Navarro J and Ferszt R eds) pp 69-74, Raven Press, New York.
14. Fitzgerald DJ and Fitzgerald GA (1989) Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 86:7585-7589.
15. Folts JD, Detmer DE, and Nadler R (1982) Possible platelet thrombi formation in dog and human femoral artery. Tex Heart Inst J 9:19-26.
16. Gold HK, Garabedian HD, Dinsmore RE, Guerrero LJ, Cigarroa JE, Palacios IF, and Leinbach RC (1997) Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Circulation 95:1755-1759.
17. Grau AJ, Ruf A, Vogt A, Lichy C, Buggle F, Patscheke H, and Hacke W (1998) Increased fraction of circulating activated platelets in acute and previous cerebrovascular ischemia. Thromb Haemostasis 80:298-301.
18. Heye N and Cervós-Navarro J (1996) Microthromboemboli in acute infarcts: analysis of 40 autopsy cases. Stroke 27:431-434.
19. 2, ADP and thrombin in thrombogenesis in the guinea pig. Eur J Pharmacol 231:421-425.
20. International Stroke Trial Collaborative Group (1997) The international stroke trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 349:1569-1581.
21. Kaku S, Umemura K, Mizuno A, Kawasaki T, and Nakashima M (1997) Evaluation of the disintegrin, triflavin, in a rat middle cerebral artery thrombosis model. Eur J Pharmacol 321:301-305.
22. Kaku S, Umemura K, Mizuno A, Yano S, Suzuki K, Kawasaki T, and Nakashima M (1998) Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis. Eur J Pharmacol 345:185-192.
23. Kawai H, Umemura K, and Nakashima M (1995) Effect of argatroban on microthrombi formation and brain damage in the rat middle cerebral artery thrombosis model. Jpn J Pharmacol 69:143-148.
24. Kawai H, Yuki S, Sugimoto J, and Tamao Y (1996) Effect of a thrombin inhibitor, argatroban, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 278:780-785.
25. Kawano K, Fujishima K, Ikeda Y, Kondo K, and Umemura K (2000) ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab 20:988-997.
26. Kawano K, Ikeda Y, Kondo K, and Umemura K (1998) Increased cerebral infarction by cyclic flow reductions: studies in the guinea pig MCA thrombosis model. Am J Physiol 275:R1578-R1583.
27. Kawano K, Ikeda Y, Kondo K, and Umemura K (1999) Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery. Eur J Pharmacol 374:377-385.
28. 2 steal" mechanism. Jpn Circ J 50:1071-1078.
29. 2 for their receptor are similar in washed human platelets. Biochem Biophys Res Commun 157:733-739.
30. Morris DC, Zhang L, Zhang ZG, Lu M, Berens KL, Brown PM, and Chopp M (2001) Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke 32:2635-2640.
31. Mousa SA, Forsythe MS, Diemer M, Bozarth JM, and Reilly TM (1994) Thrombolytic and antithrombotic efficacy of the platelet GPIIb-IIIa antagonist DMP728. Coron Artery Dis 5:919-927.
32. Nishiyama H, Umemura K, Saniabadi AR, Takiguchi Y, Uematsu T, and Nakashima M (1994) Enhancement of thrombolytic efficacy of tissue-type plasminogen activator by adjuvants in the guinea pig thrombosis model. Eur J Pharmacol 264:191-198.
33. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, and Ruoslahti E (1986) Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp-specific adhesion receptors. Science (Wash DC) 231:1559-1562.
34. Saniabadi AR, Umemura K, Matsumoto N, Sakuma S, and Nakashima M (1995) Vessel wall injury and arterial thrombosis induced by a photochemical reaction. Thromb Haemostasis 73:868-872.
35. IIbβ3 (GPIIb/IIIa) antagonists, c7E3 and DMP728. Thromb Res 88:137-146.
36. 2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model. Stroke 24:1077-1082.
37. 1α in patients with ischemic cerebrovascular disease. Stroke 16:241-244.
38. van Kooten F, Ciabattoni G, Patrono C, Schmitz PIM, van Gijn J, and Koudstaal PJ (1994) Evidence for episodic platelet activation in acute ischemic stroke. Stroke 25:278-281.
39. von Kummer R, Holle R, Rosin L, Forsting M, and Hacke W (1995) Does arterial recanalization improve outcome in carotid territory stroke? Stroke 26:581-587.
40. Wallace RC, Furlan AJ, Moliterno DJ, Stevens GH, Masaryk TJ, and Perl J 2nd (1997) Basilar artery rethrombosis: successful treatment with platelet glycoprotein IIB/IIIA receptor inhibitor. Am J Neuroradiol 18:1257-1260.
41. Zeller JA, Tschoepe D, and Kessler C (1999) Circulating platelets show increased activation in patients with acute cerebral ischemia. Thromb Haemostasis 81:373-377.